Sugi Predict

Sugi Predict / Compounds / SCHEMBL2558734

SCHEMBL2558734

SCHEMBL2558734

O=C(NCCO)c1ccc([N+](=O)[O-])cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.69
▸ RAB9A P51151 4/20 0.66
▸ NPC1 O15118 3/20 0.66
▸ SMN1; SMN2 Q16637 3/20 0.66
▸ MEN1 O00255 3/20 0.66
▸ KMT2A Q03164 3/20 0.66
▸ TAAR1 Q96RJ0 1/20 0.66
▸ ALDH1A1 P00352 2/20 0.61
▸ HDAC3 O15379 2/20 0.61
▸ HDAC1 Q13547 2/20 0.61
▸ HDAC2 Q92769 2/20 0.61
▸ HDAC4 P56524 1/20 0.61
▸ HDAC7 Q8WUI4 1/20 0.61
▸ HDAC10 Q969S8 1/20 0.61
▸ HDAC11 Q96DB2 1/20 0.61
▸ HDAC8 Q9BY41 1/20 0.61
▸ HDAC6 Q9UBN7 1/20 0.61
▸ HDAC9 Q9UKV0 1/20 0.61
▸ HDAC5 Q9UQL6 1/20 0.61
▸ GAA P10253 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11621538 0.91 MAPT (0.81) MAPTRAB9ANPC1SMN1; SMN2MEN1
SCHEMBL7210108 0.90 HDAC1 (0.66) MAPTRAB9ANPC1SMN1; SMN2MEN1
SCHEMBL23842313 0.86 HDAC1 (0.78) MAPTRAB9ANPC1SMN1; SMN2MEN1
SCHEMBL8612164 0.86 HDAC1 (0.78) MAPTRAB9ANPC1SMN1; SMN2MEN1
SCHEMBL10604485 0.86 MAPT (0.64) MAPTRAB9ANPC1SMN1; SMN2MEN1
SCHEMBL9389056 0.85 MAPT (0.68) MAPTRAB9ANPC1SMN1; SMN2MEN1
SCHEMBL6268978 0.85 MAPT (0.68) MAPTRAB9ANPC1SMN1; SMN2MEN1
SCHEMBL5610870 0.85 MAPT (0.68) MAPTRAB9ANPC1SMN1; SMN2MEN1
SCHEMBL4903476 0.85 MAPT (0.68) MAPTRAB9ANPC1SMN1; SMN2MEN1
SCHEMBL3704980 0.85 MAPT (0.68) MAPTRAB9ANPC1SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109456215-B Functional diamine monomer with high planarity and containing fluorene or fluorenone structure as well as synthesis method and application thereof 湖南工业大学 2021-10-01 — — CN disclosed
CN-109456215-A Contain fluorenes or Fluorenone structure function diamine monomer and its synthetic method and application with high flatness 湖南工业大学 2019-03-12 — — CN disclosed
CN-105693539-B Diamine monomer containing fluorene or fluorenone structure and having high planarity as well as synthesis method and application thereof 湖南工业大学 2019-01-25 — — CN disclosed
EP-2760492-B1 BALLOON CATHETER WITH POLYMERIC BALLOON HAVING A SURFACE MODIFIED BY A PHOTOACTIVATION REACTION AND METHOD FOR MAKING INVATEC SPA (IT) 2018-10-31 — — EP disclosed
US-9956318-B2 Balloon catheter with polymeric balloon having a surface modified by a photoactivation reaction and method for making INVATEC S.P.A. (IT) 2018-05-01 — — US disclosed
EP-2560695-B1 PHOTOACTIVATED POLYMERIC MATERIAL AND ITS USE FOR THE PREPARATION OF MEDICAL DEVICES INVATEC SPA (IT) 2018-02-21 — — EP disclosed
US-20170119935-A1 BALLOON CATHETER WITH POLYMERIC BALLOON HAVING A SURFACE MODIFIED BY A PHOTOACTIVATION REACTION AND METHOD FOR MAKING INVATEC S.P.A. (IT) 2017-05-04 — — US disclosed
US-9550047-B2 Balloon catheter with polymeric balloon having a surface modified by a photoactivation reaction and method of making INVATEC S.P.A. (IT) 2017-01-24 — — US disclosed
CN-105693539-A Diamine monomer containing fluorene or fluorenone structure and having high planarity as well as synthesis method and application thereof 湖南工业大学 2016-06-22 — — CN disclosed
CN-105367509-A Polymer-filler coupling additives BRIDGESTONE CORP 2016-03-02 — — CN disclosed
WO-2012059932-A1 2, 4 -DIAMINOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2012-05-10 — — WO disclosed
WO-2012059932-A1 2, 4 -DIAMINOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2012-05-10 — — WO disclosed
WO-2011131222-A1 PHOTOACTIVATED POLYMERIC MATERIAL AND ITS USE FOR THE PREPARATION OF MEDICAL DEVICES INVATEC S.P.A. (IT) 2011-10-27 — — WO disclosed
WO-2011131677-A1 PHOTOACTIVATED POLYMERIC MATERIAL AND ITS USE FOR THE PREPARATION OF MEDICAL DEVICES INVATEC S.P.A. (IT) 2011-10-27 — — WO disclosed
EP-1802593-A2 POLYMER-FILLER COUPLING ADDITIVES Bridgestone Corporation (JP) 2007-07-04 — — EP disclosed
US-20060276433-A1 Hydrazone derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-12-07 — — US disclosed
WO-2006045088-A2 POLYMER-FILLER COUPLING ADDITIVES BRIDGESTONE CORPORATION (JP) 2006-04-27 — — WO disclosed
EP-1612204-A1 HYDRAZONE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-01-04 — — EP disclosed
WO-1993012132-A1 PHOSPHOTRIESTERS OF 2',3'-DIDEOXY-URIDINE, METHOD FOR PREPARING SAME, AND THERAPEUTICAL USES THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 1993-06-24 — — WO disclosed
US-4412992-A 2-Hydroxy-5-phenylazobenzoic acid derivatives and method of treating ulcerative colitis therewith BIOREX LABORATORIES LIMITED (GB) 1983-11-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276433-A1 Hydrazone derivative APP, PRNP, HTT MAPT 94/4885RAB9A 3127/4885NPC1 952/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.